|
| Press Releases |
|
 |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
| Monday, January 18, 2021 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
| Monday, November 23, 2020 |
|
|
SinoMab Commenced Construction of its China Headquarters |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, July 23, 2020 |
|
|
SinoMab entered into Strategic Collaboration with D2M |
| SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, June 10, 2020 |
|
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Wednesday, October 30, 2019 |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Global Crypto Leaders to Converge in Dubai for Historic 30th Edition of HODL
May 9, 2025 23:16 HKT/SGT
|
|
|
ZA Miner Expands Cloud Mining Platform with Clean Energy Infrastructure and Increased Global Adoption 
May 9, 2025 20:00 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance
May 9, 2025 18:57 JST
|
|
|
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 9, 2025 18:00 JST
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 9, 2025 17:00 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 9, 2025 16:45 HKT/SGT
|
|
|
Nestle and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona
May 9, 2025 16:20 HKT/SGT
|
|
|
Thailand, Led by DPM Prasert, to Showcase Leadership in Hosting the 3rd UNESCO Global Forum on the Ethics of AI 2025
May 9, 2025 15:30 HKT/SGT
|
|
|
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 9, 2025 16:03 JST
|
|
|
Solar & Storage Live Philippines 2025 Powers Up to Drive the Nation's Clean Energy Future
May 9, 2025 14:28 HKT/SGT
|
|
|
Ensign InfoSecurity Recognised in MITRE's 2024 Impact Report for Contribution to Global Cyber Defence Research
May 9, 2025 11:00 HKT/SGT
|
|
|
Unlocking the Full Potential of GCCs: The Strategic Power of Cultural Integration
May 9, 2025 02:53 HKT/SGT
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 9, 2025 02:14 HKT/SGT
|
|
|
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft
May 9, 2025 00:00 HKT/SGT
|
|
|
The 33rd China Cycle 2025 Grandly Commences
May 8, 2025 17:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
